Home Medizin Akeros Medikament gegen Fettleber lindert Narbenbildung in einer Studie im mittleren Stadium

Akeros Medikament gegen Fettleber lindert Narbenbildung in einer Studie im mittleren Stadium

von NFI Redaktion

(Reuters) – An intermediate study showed that Akero Therapeutics‘ experimental drug for a type of fatty liver disease significantly reduced scarring after almost two years, the company targeting a potential multi-billion dollar market reported on Monday.

The company’s stock rose 19% to $33.09 in morning trading, with at least one analyst stating that the drug demonstrated the most benefit in the small study compared to any other treatment tested in separate studies for the disease.

However, the results need to be confirmed in a later trial.

Based in South San Francisco, California, Akero tested the drug Efruxifermin in an intermediate study involving 128 patients with metabolic dysfunction-associated steatohepatitis (MASH) with scarring or fibrosis at severity levels two or three.

For the condition previously known as non-alcoholic steatohepatitis (NASH), there are no approved drugs. The U.S. Food and Drug Administration is expected to make a decision on competitor Madrigal Pharmacauticals‘ drug by next Thursday.

„I think whoever gets approved first needs to build this market,“ said Kitty Yale, Akero’s Chief Development Officer, in an interview.

„Then you can benefit from it… with drugs that have a stronger overall efficacy profile,“ she said.

After 96 weeks, biopsies of 88 patients showed that Efruxifermin helped reduce liver scarring by at least one stage in 75% of patients taking the higher dose and 46% of patients taking a lower dose, compared to 24% on placebo.

It helped reduce scarring by at least two stages in over a third of patients taking the higher dose and 31% in the lower dose, compared to 3% of patients on placebo, according to Akero.

The data exceeded investor expectations, said Jefferies analyst Michael Yee in a statement, predicting peak sales of the drug at $2 to $3 billion.

According to Akero, NASH or MASH causes an excessive accumulation of fat in the liver and affects more than 17 million Americans. NeuroBo Pharmaceuticals and 89bio are also developing treatments for the disease.

(Reporting by Leroy Leo and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber and Sriraj Kalluvila)

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.